“Secukinumab Treatment in Patients with Spondyloarthritis and Concomitant Demyelinating Disease: Rationale of IL-17 Inhibition and Clinical Outcome”, acmcr, vol. 6, no. 5, pp. 660–668, Oct. 2022, Accessed: Sep. 11, 2026. Available: https://fortunejournals.org/ojs/index.php/acmcr/article/view/22670